Literature DB >> 31365499

Is it time to fund routine NHS usage of PSMA PET-CT?

Asim Afaq1, Peter J Ell, Jamshed B Bomanji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31365499     DOI： 10.1097/MNM.0000000000001066

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


× No keyword cloud information.
  3 in total

1.  Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.

Authors:  Ian Leigh Alberts; Svenja Elizabeth Seide; Clemens Mingels; Karl Peter Bohn; Kuangyu Shi; Helle D Zacho; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

2.  A Phase II, Open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study.

Authors:  Asim Afaq; Heather Payne; Reena Davda; John Hines; Gary J R Cook; Marie Meagher; Dimitrios Priftakis; Victoria S Warbey; Anand Kelkar; Clement Orczyk; Anita Mitra; Sarah Needleman; Michael Ferris; Greg Mullen; Jamshed Bomanji
Journal:  J Nucl Med       Date:  2021-03-19       Impact factor: 11.082

3.  Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer.

Authors:  Clemens Mingels; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh; Ian Alberts
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-24       Impact factor: 10.057
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.